NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 1 filers reported holding NABRIVA THERAPEUTICS PLC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,000 | -50.0% | 3,000 | -40.0% | 0.00% | -100.0% |
| Q1 2022 | $2,000 | -33.3% | 5,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $3,000 | -50.0% | 5,000 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $6,000 | -14.3% | 5,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $7,000 | -12.5% | 5,000 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $8,000 | -33.3% | 5,000 | 0.0% | 0.00% | -25.0% |
| Q4 2020 | $12,000 | -25.0% | 5,000 | -83.3% | 0.00% | -33.3% |
| Q3 2020 | $16,000 | -20.0% | 30,000 | 0.0% | 0.01% | -25.0% |
| Q2 2020 | $20,000 | +17.6% | 30,000 | 0.0% | 0.01% | -11.1% |
| Q1 2020 | $17,000 | -34.6% | 30,000 | +50.0% | 0.01% | -25.0% |
| Q4 2019 | $26,000 | -35.0% | 20,000 | 0.0% | 0.01% | -40.0% |
| Q3 2019 | $40,000 | +66.7% | 20,000 | +100.0% | 0.02% | +66.7% |
| Q2 2019 | $24,000 | 0.0% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $24,000 | +71.4% | 10,000 | 0.0% | 0.01% | +50.0% |
| Q4 2018 | $14,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,074,190 | $33,368,000 | 6.74% |
| Novo Holdings A/S | 2,903,800 | $23,782,000 | 3.10% |
| PURA VIDA INVESTMENTS, LLC | 425,000 | $3,481,000 | 1.02% |
| ACUTA CAPITAL PARTNERS, LLC | 400,000 | $3,276,000 | 0.59% |
| Monashee Investment Management LLC | 188,000 | $1,540,000 | 0.58% |
| Orbimed Advisors | 3,919,600 | $32,102,000 | 0.31% |
| FT Options LLC | 20,000 | $164,000 | 0.25% |
| Rock Springs Capital Management LP | 625,000 | $5,119,000 | 0.24% |
| Rubric Capital Management LP | 300,000 | $2,457,000 | 0.22% |
| Ghost Tree Capital, LLC | 120,000 | $983,000 | 0.21% |